<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01800825</url>
  </required_header>
  <id_info>
    <org_study_id>Thrasher (DDD# 601465)</org_study_id>
    <nct_id>NCT01800825</nct_id>
  </id_info>
  <brief_title>Clindamycin to Reduce Preterm Birth in a Low Resource Setting</brief_title>
  <official_title>Clindamycin to Reduce Preterm Birth in a Low Resource Setting: A Randomized Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christiana Care Health Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jawaharlal Nehru Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Christiana Care Health Services</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm birth has been linked to certain types of vaginal infections. The goal of this study
      is to determine if giving women pregnant between 13-20 weeks with an elavated vaginal
      pH(evidence of this type of infection)Oral Clindamycin(an antibiotic)will have a lower rate
      of preterm birth compared to women given a placebo(starch)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary study objective is to definitively test whether 300 mg oral clindamycin two times
      per day for 5-days administered at 13-20 weeks of gestation in women with a vaginal pH≥5
      reduces the incidence of preterm delivery in Karnataka, India by at least 30%. The national
      incidence of gestation &lt;37 weeks in India is 14.5%, was 18% in the study area in 2011 and was
      20% among women with vaginal pH≥5 in the recently completed Jawaharlal Nehru Medical Collage
      (JNMC) hospital-based study of clindamycin to reduce preterm birth. Using a two tailed test,
      α=0.05, 1-β=80%, a 17.5% rate of prematurity in women with vaginal pH≥5, a 2.5% refusal and a
      7.5% loss to follow-up, assuming 86% of women presenting for antenatal care are 13-20 weeks
      gestation and 1% otherwise ineligible, and a multiple comparisons adjustment, 1,726 women,
      half in the clindamycin and half in the placebo group, need to be enrolled to test the
      primary hypothesis. The effects of clindamycin on spontaneous preterm birth, miscarriage, low
      birthweight (LBW), neonatal mortality (NMR), maternal and neonatal complications through 42
      days postpartum, the utility of vaginal pH≥5 to identify women at risk for preterm delivery
      and the costs of preterm birth prevented by oral clindamycin treatment and compliance with
      the 5-day treatment regimen will also be assessed. This will be the first investigation to
      test whether oral clindamycin prevents preterm birth in a community-based, developing country
      setting, where most global newborn deaths occur.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preterm birth prior to 37 weeks</measure>
    <time_frame>Time of birth</time_frame>
    <description>Preterm birth prior to 37 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preterm birth prior to 34 weeks</measure>
    <time_frame>Time of birth</time_frame>
    <description>Preterm birth prior to 34 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Miscarriage</measure>
    <time_frame>Time of delivery</time_frame>
    <description>miscarriage between 16-20 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Birth weight</measure>
    <time_frame>Time of delivery</time_frame>
    <description>Birth Weight&lt; 2500 gm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very Low birth Weight</measure>
    <time_frame>Time of delivery</time_frame>
    <description>Very Low birth Weight is birthweight &lt;1500gm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal complications through 42 days after delivery</measure>
    <time_frame>42 days post delivery</time_frame>
    <description>Neonatal complications through 42 days after delivery (to assess benefit or no harm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal complications through 42 days postpartum</measure>
    <time_frame>42 days post delivery</time_frame>
    <description>Maternal complications through 42 days postpartum (to assess benefit or no harm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The utility of vaginal pH tests for identification of women at elevated risk for preterm delivery</measure>
    <time_frame>Time of delivery</time_frame>
    <description>The utility of vaginal pH tests for identification of women at elevated risk for preterm delivery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>neonatal mortality</measure>
    <time_frame>Time of delivery</time_frame>
    <description>neonatal mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>maternal and neonatal complications through 42 days postpartum,</measure>
    <time_frame>42 days postpartum</time_frame>
    <description>maternal and neonatal complications through 42 days postpartum,</description>
  </other_outcome>
  <other_outcome>
    <measure>Incremental cost of preventing preterm birth</measure>
    <time_frame>42 days postpartum</time_frame>
    <description>Determine the costs of preventing preterm birth</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1726</enrollment>
  <condition>Pregnancy</condition>
  <condition>Prematurity</condition>
  <condition>Preterm Birth</condition>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>Clindamycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clindamycin 300mg orally twice daily for five days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This will be an identical placebot</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin</intervention_name>
    <description>Clindamycin 300 mg Orally will be administered twice daily for a total of 5 days</description>
    <arm_group_label>Clindamycin</arm_group_label>
    <other_name>Cleocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This will be an identical placebo comparator made of starch.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with a singleton Intrauterine pregnancy between 13-20 weeks

          -  Maternal age of 18 or older or if &lt; 18 assent of the women's parent/guardian

          -  Vaginal PH &gt; 5.0

        Exclusion Criteria:

          -  Use of antibiotics within the 14 days prior to randomization

          -  Known sensitivity to antibiotics

          -  Uterine anomalies

          -  Major fetal anomalies

          -  Medical conditions that may result in iatrogenic prematurity(e.g.diabetes, Lupus,
             Hypertension)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew K Hoffman, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christiana Care Health Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jawaharlal Nehru Medical College</name>
      <address>
        <city>Belgaum</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.thrasherresearch.org/</url>
    <description>Thrasher Foundation</description>
  </link>
  <reference>
    <citation>Lamont RF, Nhan-Chang CL, Sobel JD, Workowski K, Conde-Agudelo A, Romero R. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol. 2011 Sep;205(3):177-90. doi: 10.1016/j.ajog.2011.03.047. Epub 2011 Apr 2. Review.</citation>
    <PMID>22071048</PMID>
  </reference>
  <reference>
    <citation>Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet. 2003 Mar 22;361(9362):983-8.</citation>
    <PMID>12660054</PMID>
  </reference>
  <reference>
    <citation>Lawn JE, Cousens S, Zupan J; Lancet Neonatal Survival Steering Team. 4 million neonatal deaths: when? Where? Why? Lancet. 2005 Mar 5-11;365(9462):891-900.</citation>
    <PMID>15752534</PMID>
  </reference>
  <reference>
    <citation>Lawn JE, Blencowe H, Pattinson R, Cousens S, Kumar R, Ibiebele I, Gardosi J, Day LT, Stanton C; Lancet's Stillbirths Series steering committee. Stillbirths: Where? When? Why? How to make the data count? Lancet. 2011 Apr 23;377(9775):1448-63. doi: 10.1016/S0140-6736(10)62187-3. Epub 2011 Apr 13.</citation>
    <PMID>21496911</PMID>
  </reference>
  <reference>
    <citation>Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008 Jan 5;371(9606):75-84. doi: 10.1016/S0140-6736(08)60074-4. Review.</citation>
    <PMID>18177778</PMID>
  </reference>
  <reference>
    <citation>Friese K. The role of infection in preterm labour. BJOG. 2003 Apr;110 Suppl 20:52-4. Review.</citation>
    <PMID>12763112</PMID>
  </reference>
  <reference>
    <citation>Hauth JC, Goldenberg RL, Andrews WW, DuBard MB, Copper RL. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med. 1995 Dec 28;333(26):1732-6.</citation>
    <PMID>7491136</PMID>
  </reference>
  <reference>
    <citation>Hutzal CE, Boyle EM, Kenyon SL, Nash JV, Winsor S, Taylor DJ, Kirpalani H. Use of antibiotics for the treatment of preterm parturition and prevention of neonatal morbidity: a metaanalysis. Am J Obstet Gynecol. 2008 Dec;199(6):620.e1-8. doi: 10.1016/j.ajog.2008.07.008. Epub 2008 Oct 30. Review.</citation>
    <PMID>18973872</PMID>
  </reference>
  <reference>
    <citation>McDonald HM, Brocklehurst P, Gordon A. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD000262. Review. Update in: Cochrane Database Syst Rev. 2013;1:CD000262.</citation>
    <PMID>17253447</PMID>
  </reference>
  <reference>
    <citation>Joesoef MR, Hillier SL, Wiknjosastro G, Sumampouw H, Linnan M, Norojono W, Idajadi A, Utomo B. Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. Am J Obstet Gynecol. 1995 Nov;173(5):1527-31.</citation>
    <PMID>7503196</PMID>
  </reference>
  <reference>
    <citation>Lamont RF. Antibiotics for the prevention of preterm birth. N Engl J Med. 2000 Feb 24;342(8):581-3.</citation>
    <PMID>10684919</PMID>
  </reference>
  <reference>
    <citation>Guaschino S, Ricci E, Franchi M, Frate GD, Tibaldi C, Santo DD, Ghezzi F, Benedetto C, Seta FD, Parazzini F. Treatment of asymptomatic bacterial vaginosis to prevent pre-term delivery: a randomised trial. Eur J Obstet Gynecol Reprod Biol. 2003 Oct 10;110(2):149-52.</citation>
    <PMID>12969574</PMID>
  </reference>
  <reference>
    <citation>Kurkinen-Räty M, Vuopala S, Koskela M, Kekki M, Kurki T, Paavonen J, Jouppila P. A randomised controlled trial of vaginal clindamycin for early pregnancy bacterial vaginosis. BJOG. 2000 Nov;107(11):1427-32.</citation>
    <PMID>11117774</PMID>
  </reference>
  <reference>
    <citation>Kekki M, Kurki T, Pelkonen J, Kurkinen-Räty M, Cacciatore B, Paavonen J. Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial. Obstet Gynecol. 2001 May;97(5 Pt 1):643-8.</citation>
    <PMID>11339909</PMID>
  </reference>
  <reference>
    <citation>Morency AM, Bujold E. The effect of second-trimester antibiotic therapy on the rate of preterm birth. J Obstet Gynaecol Can. 2007 Jan;29(1):35-44. Review.</citation>
    <PMID>17346476</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2013</study_first_submitted>
  <study_first_submitted_qc>February 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2013</study_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Christiana Care Health Services</investigator_affiliation>
    <investigator_full_name>Matthew Hoffman</investigator_full_name>
    <investigator_title>Vice Chair of Department of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Prematurity</keyword>
  <keyword>Preterm birth</keyword>
  <keyword>bacterial vaginosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

